Gastrointestinal and hematologic adverse events after administration of vincristine, cyclophosphamide, and doxorubicin in dogs with lymphoma that underwent a combination multidrug chemotherapy protocol

Journal of Veterinary Medical Science

Volumn 72, Issue 11, 2010, Pages 1391-1397

  Tomiyasu, Hirotaka ^a   Takahashi, Masashi ^a   Fujino, Yasuhito ^a   OHNO, Koichi ^a   TSUJIMOTO, Hajime ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Adverse event; Canine; Lymphoma; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; VINCRISTINE;

ANIMAL; ANIMAL DISEASE; ARTICLE; BONE MARROW; CANCER STAGING; DOG; DOG DISEASE; DRUG EFFECT; FEMALE; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; MALE; MORTALITY; NONHODGKIN LYMPHOMA; ORCHIECTOMY; OVARIECTOMY; PATHOLOGY; RECURRENT DISEASE; RETROSPECTIVE STUDY; TREATMENT FAILURE; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CYCLOPHOSPHAMIDE; DOG DISEASES; DOGS; DOXORUBICIN; FEMALE; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; LYMPHOMA, NON-HODGKIN; MALE; NEOPLASM STAGING; ORCHIECTOMY; OVARIECTOMY; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT FAILURE; TREATMENT OUTCOME; VINCRISTINE;

CANIS FAMILIARIS;

EID: 78649801594     PISSN: 09167250     EISSN: 13477439     Source Type: Journal    
DOI: 10.1292/jvms.10-0176     Document Type: Article

References (11)

1. Dennison, J. B., Kulanthaivel, P., Barbuch, R. J., Renbarger, J. L., Ehlhardt, W. J. and Hall, S. D. 2006. Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab. Dispos. 34: 1317-1327.
2. Garrett, L. D., Thamm, D. H., Chun, R., Dudley, R. and Vail, D. M. 2002. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J. Vet. Intern. Med. 16: 704-709.
3. Hume, K. R., Johnson, J. L. and Williams, L. E. 2009. Adverse effects of concurrent carboplatin chemotherapy and radiation therapy in dogs. J. Vet. Intern. Med. 23: 24-30.
4. Moore, A. S., Cotter, S. M., Rand, W. M., Wood, C. A., Williams, L. E., London, C. A., Frimberger, A. E. and L'Heureux, D. A. 2001. Evaluation of a discontinuous treatment protocol (VELCAP-S) for canine lymphoma. J. Vet. Intern. Med. 15: 348-354.
5. Myers, N. C., 3rd, Moore, A. S., Rand, W. M., Gliatto, J. and Cotter, S. M. 1997. Evaluation of a multidrug chemotherapy protocol (ACOPA II) in dogs with lymphoma. J. Vet. Intern. Med. 11: 333-339.
6. Owen, L. N. 1981. TNM Classification of Tumors in Domestic Animals. Geneva: World Health Organization
7. Roy, J. N., Lajoie, J., Zijenah, L. S., Barama, A., Poirier, C., Ward, B. J. and Roger, M. 2005. CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab. Dispos. 33: 884-887.
8. Trotti, A., Colevas, A. D., Setser, A., Rusch, V., Jaques, D., Budach, V., Langer, C., Murphy, B., Cumberlin, R., Coleman, C. N. and Rubin, P. 2003. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin. Radiat. Oncol. 13: 176-181.
9. Vaughan, A., Johnson, J. L. and Williams, L. E. 2007. Impact of chemotherapeutic dose intensity and hematologic toxicity on first remission duration in dogs with lymphoma treated with a chemoradiotherapy protocol. J. Vet. Intern. Med. 21: 1332-1339.
10. Veterinary Co-operative Oncology Group. 2004. Veterinary co-operative oncology group common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0 Vet. Compar. Oncol. 2: 194-213.
11. Zemann, B. I., Moore, A. S., Rand, W. M., Mason, G., Rus-lander, D. M., Frimberger, A. E., Wood, C. A., L'Heureux, D. A., Gliatto, J. and Cotter, S. M. 1998. A combination chemotherapy protocol (VELCAP-L) for dogs with lymphoma. J. Vet. Intern. Med. 12: 465-470.